Rebecca Hartzog
Psychiatric/Mental Health · Hattiesburg, MSNPI 1215267018
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 58.2% of the total. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 525 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$950
- Teva Pharmaceuticals USA, Inc.$720
- Takeda Pharmaceuticals U.S.A., Inc.$620
- Corium, LLC$563
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$8,37548%
- Travel & lodging$730%
- Food & beverage$8,96951%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $10,168 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $1,323 |
| Axsome Therapeutics, Inc. | 48 | $950 |
| Teva Pharmaceuticals USA, Inc. | 33 | $720 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $620 |
| Corium, LLC | 35 | $563 |
| Lundbeck LLC | 29 | $516 |
| Otsuka America Pharmaceutical, Inc. | 24 | $512 |
| Vanda Pharmaceuticals Inc. | 23 | $427 |
| Supernus Pharmaceuticals, Inc. | 20 | $377 |
| Alkermes, Inc. | 12 | $226 |
| Johnson & Johnson | 16 | $209 |
| Collegium Pharmaceutical, Inc. | 12 | $193 |
| Neurocrine Biosciences, Inc. | 7 | $166 |
| Ironshore Pharmaceuticals Inc. | 8 | $156 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Avanir Pharmaceuticals, Inc. | 6 | $100 |
| Tris Pharma Inc | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| CSL Behring | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,468 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $190,356 |
| CaplytaLumateperone Tosylate | 35 | $69,522 |
| VraylarCariprazine Hcl | 41 | $59,065 |
| RexultiBrexpiprazole | 24 | $33,033 |
| Oxcarbazepine | 48 | $3,178 |
| Fluvoxamine Maleate | 20 | $1,410 |
| Ziprasidone Hcl | 40 | $1,108 |
| Duloxetine Hcl | 56 | $1,077 |
| Fluoxetine Hcl | 40 | $862 |
| Sertraline Hcl | 84 | $796 |
| Lamotrigine | 76 | $717 |
| Aripiprazole | 41 | $700 |
| Buspirone Hcl | 50 | $669 |
| Bupropion Hcl SrBupropion Hcl | 27 | $629 |
| Quetiapine Fumarate | 49 | $619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $720 | $190,35613 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,323 | $69,52235 claims |
| AbbVieVraylar | $10,168 | $59,06541 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $512 | $33,03324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Hattiesburg
- Leigh CalcoteHattiesburg$15K
- Lisa DabbsHattiesburg$11K
- Justin TaylorHattiesburg$4K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.